Abstract:Abstract Breast cancer stemness is one of the drivers of metastatic spread and presents a key target in the battle against metastatic disease, especially in triple-negative breast cancer (TNBC). Existing treatment options for TNBC are limited due to recurrence and resistance, representing a major unmet clinical need. MicroRNA-10b (miR-10b) is one of the major drivers of breast cancer cell migration and invasion. In our earlier studies, we discovered that miR-10b is also responsible for metastatic cell viability. With the goal of translation of this finding to the clinic, we developed a novel therapeutic, or “nanodrug,” that targets miR-10b, consisting of antisense anti-miR-10b oligonucleotides conjugated to magnetic nanoparticles (MN) that serve as delivery vehicles. Administration of the nanodrug in mice bearing metastatic MDA-MB-231 TNBC tumors prevents the development of metastases and stops the growth of pre-existing metastases. Additionally, combination treatment with adjuvant doxorubicin induced a stable regression of metastases in immunocompromised and immunocompetent mouse models of metastatic TNBC. A limitation of our previous studies is the lack of understanding of the molecular basis for the therapeutic effect of MN-anti-miR10b. To address this gap in knowledge, we performed RNA sequencing on MDA-MB-231 cells treated with the nanodrug or controls. Functional enrichment analysis of differentially expressed genes (DEGs) between cells treated with the nanodrug versus controls (PBS or bare MN) identified a significant overrepresentation of genes associated with cell differentiation. It has been suggested that miR-10b confers stem cell-like properties such as self-renewal and drug resistance onto cancer cells. Our RNA sequencing findings led us to hypothesize that MN-anti-miR10b functions by inhibiting these stem-like cancer cell (CSC) features that are critical to cancer survival. Here, we present preliminary data showing that miR-10b is overexpressed in MDA-MB-231 cells expressing a CSC-associated surface marker phenotype (CD44+/CD24-, compared to CD44-/CD24- cells) and that this trend is not universal among other miRNAs. Furthermore, we found that the nanodrug interferes with the ability of cells to assemble as spheroids, a property associated with CSCs. With our recent observation that the nanodrug inhibits miR-10b in metastases in vivo in as little as one dose after 72 hours, our next steps are to determine whether the cell differentiation-associated DEGs identified in RNA sequencing results can be used as biomarkers of nanodrug efficacy in vivo. Understanding the changes in gene expression induced by MN-anti-miR10b as a function of time will be critical for guiding treatment regimens in future preclinical and clinical trials. Citation Format: Alan Halim, Nasreen Al-Qadi, Sujan K. Mondal, Elizabeth Kenyon, N. Anna Savan, Hussein Mackie, Anna Moore. Identification of efficacy biomarkers for therapies targeting miR-10b [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4726.

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Nanoparticle-based MRI of metastatic human hepatocellular carcinoma: Targeting survivin gene with siRNA in an animal model

Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo

Multifunctional and Multiplexed Nanoparticles for Molecular Imaging and Treatment of Breast Cancer

Abstract 4726: Identification of efficacy biomarkers for therapies targeting miR-10b

Receptor-Targeted Nanoparticles for in Vivo Imaging of Breast Cancer

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Biomimetic bright optotheranostics for metastasis monitoring and multimodal image-guided breast cancer therapeutics

Novel Multifunctional Magnetic Nanoparticles：An Efficient Theranostic Platform for Magnetic Resonance Imaging and Targeted Therapy of Cervical Cancer

Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles

In vivo murine breast cancer targeting by magnetic iron nanoparticles involving L. GG cytoplasmic fraction

Magnetic Targeting and Ultrasound Activation of Liposome-Microbubble Conjugate for Enhanced Delivery of Anti-Cancer Therapies.

Monitoring the Progression of Metastatic Breast Cancer on Nanoporous Silica Chips

Real-Time in Vivo Quantitative Monitoring of Drug Release by Dual-Mode Magnetic Resonance and Upconverted Luminescence Imaging

Targeted MRI and Chemotherapy of Ovarian Cancer with Clinic Available Nano-Drug Based Nanoprobe.

Superparamagnetic iron oxide nanoparticles conjugated with doxorubicin for targeting breast cancer

Magnetic Nanoliposomes As in Situ Microbubble Bombers for Multimodality Image-Guided Cancer Theranostics.

Upconversion-Nanoparticle-Based Smart Drug-Delivery Platforms for Multimodal Imaging-Guided Cancer Therapies

Tumor Cell Membrane‐Camouflaged Vortex Magnetic Nanoannulars Programmed by Low‐Frequency Magnetic Field: A Novel Anti‐Cancer Delivery System in Triple‐Negative Breast Cancer

Functional Metal-Organic Framework-Based Nanocarriers for Accurate Magnetic Resonance Imaging and Effective Eradication of Breast Tumor and Lung Metastasis

A Tumor-specific MicroRNA Recognition System Facilitates the Accurate Targeting to Tumor Cells by Magnetic Nanoparticles